BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10680842)

  • 1. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect.
    Stribbling SM; Friedlos F; Martin J; Davies L; Spooner RA; Marais R; Springer CJ
    Hum Gene Ther; 2000 Jan; 11(2):285-92. PubMed ID: 10680842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.
    Friedlos F; Davies L; Scanlon I; Ogilvie LM; Martin J; Stribbling SM; Spooner RA; Niculescu-Duvaz I; Marais R; Springer CJ
    Cancer Res; 2002 Mar; 62(6):1724-9. PubMed ID: 11912146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug.
    Spooner RA; Martin J; Friedlos F; Marais R; Springer CJ
    Cancer Gene Ther; 2000 Oct; 7(10):1348-56. PubMed ID: 11059693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy.
    Marais R; Spooner RA; Stribbling SM; Light Y; Martin J; Springer CJ
    Nat Biotechnol; 1997 Dec; 15(13):1373-7. PubMed ID: 9415889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination.
    Marais R; Spooner RA; Light Y; Martin J; Springer CJ
    Cancer Res; 1996 Oct; 56(20):4735-42. PubMed ID: 8840992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.
    Niculescu-Duvaz I; Scanlon I; Niculescu-Duvaz D; Friedlos F; Martin J; Marais R; Springer CJ
    J Med Chem; 2004 May; 47(10):2651-8. PubMed ID: 15115406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
    Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
    J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2.
    Schepelmann S; Ogilvie LM; Hedley D; Friedlos F; Martin J; Scanlon I; Chen P; Marais R; Springer CJ
    Cancer Res; 2007 May; 67(10):4949-55. PubMed ID: 17510425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
    Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Lehouritis P; Marais R; Springer CJ
    J Med Chem; 2003 Apr; 46(9):1690-705. PubMed ID: 12699387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs.
    Spooner RA; Friedlos F; Maycroft K; Stribbling SM; Roussel J; Brueggen J; Stolz B; O'Reilly T; Wood J; Matter A; Marais R; Springer CJ
    Br J Cancer; 2003 May; 88(10):1622-30. PubMed ID: 12771932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
    Davies LC; Friedlos F; Hedley D; Martin J; Ogilvie LM; Scanlon IJ; Springer CJ
    J Med Chem; 2005 Aug; 48(16):5321-8. PubMed ID: 16078849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy.
    Friedlos F; Lehouritis P; Ogilvie L; Hedley D; Davies L; Bermudes D; King I; Martin J; Marais R; Springer CJ
    Clin Cancer Res; 2008 Jul; 14(13):4259-66. PubMed ID: 18594008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
    Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2.
    Schepelmann S; Hallenbeck P; Ogilvie LM; Hedley D; Friedlos F; Martin J; Scanlon I; Hay C; Hawkins LK; Marais R; Springer CJ
    Cancer Res; 2005 Jun; 65(12):5003-8. PubMed ID: 15958540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug.
    Blakey DC; Valcaccia BE; East S; Wright AF; Boyle FT; Springer CJ; Burke PJ; Melton RG; Bagshawe KD
    Cell Biophys; 1993; 22(1-3):1-8. PubMed ID: 7889535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-immolative anthracycline prodrugs for suicide gene therapy.
    Niculescu-Duvaz I; Niculescu-Duvaz D; Friedlos F; Spooner R; Martin J; Marais R; Springer CJ
    J Med Chem; 1999 Jul; 42(13):2485-9. PubMed ID: 10395490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
    Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ
    Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.
    Blakey DC; Burke PJ; Davies DH; Dowell RI; East SJ; Eckersley KP; Fitton JE; McDaid J; Melton RG; Niculescu-Duvaz IA; Pinder PE; Sharma SK; Wright AF; Springer CJ
    Cancer Res; 1996 Jul; 56(14):3287-92. PubMed ID: 8764123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.
    Eccles SA; Court WJ; Box GA; Dean CJ; Melton RG; Springer CJ
    Cancer Res; 1994 Oct; 54(19):5171-7. PubMed ID: 7923136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft.
    Stribbling SM; Martin J; Pedley RB; Boden JA; Sharma SK; Springer CJ
    Cancer Chemother Pharmacol; 1997; 40(4):277-84. PubMed ID: 9225945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.